Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024

7/17/24 6:25:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $JNJ alert in real time by email

Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2024 of $1.24 per share on the company's common stock. The dividend is payable on September 10, 2024 to shareholders of record at the close of business on August 27, 2024. The ex-dividend date is August 27, 2024.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716315258/en/

Get the next $JNJ alert in real time by email

Date	Price Target	Rating	Analyst
11/15/2024	$190.00	Outperform	Wolfe Research
7/23/2024	$160.00 → $150.00	Outperform → Neutral	Daiwa Securities
5/30/2024	$160.00	Neutral	Goldman
4/18/2024	$170.00	Hold → Buy	HSBC Securities
12/13/2023	$170.00 → $163.00	Overweight → Equal Weight	Wells Fargo
12/1/2023	$167.00 → $180.00	Neutral → Buy	UBS
10/5/2023	$178.00	Outperform	RBC Capital Mkts
9/6/2023	$175.00	Hold	HSBC Securities

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024

Chat with this insight

Recent Analyst Ratings for $JNJ

$JNJ Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Wolfe Research initiated coverage on Johnson & Johnson with a new price target

Johnson & Johnson downgraded by Daiwa Securities with a new price target

Goldman resumed coverage on Johnson & Johnson with a new price target

$JNJ SEC Filings

SEC Form 13F-HR filed by Johnson & Johnson

SEC Form 10-Q filed by Johnson & Johnson

Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$JNJ Press Releases

Fastest customizable press release news feed in the world

Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study

$JNJ Financials

Live finance-specific insights

$JNJ Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024

Johnson & Johnson Reports Q3 2024 Results

Johnson & Johnson Completes Acquisition of V-Wave

Amendment: EVP, Innovative Medicine, R&D Reed John C converted options into 25,255 shares and covered exercise/tax liability with 10,984 shares, increasing direct ownership by 4,664% to 14,577 units (SEC Form 4)

Exec VP, CFO Wolk Joseph J gifted 68,890 shares and received a gift of 68,835 shares, closing all direct ownership in the company (SEC Form 4)

SEC Form 4 filed by Director Davis D Scott

$JNJ FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

July 21, 2023 - FDA Roundup: July 21, 2023

May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

$JNJ Leadership Updates

Live Leadership Updates

NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors

Sarepta Therapeutics Set to Join S&P MidCap 400

Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors

$JNJ Market Insights

Live Market Insights

Looking Into Johnson & Johnson's Recent Short Interest

Newly-Listed Psoriasis Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

Check Out What Whales Are Doing With JNJ

$JNJ Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Johnson & Johnson

SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

Recent Analyst Ratings for
$JNJ

$JNJ
Analyst Ratings

$JNJ
SEC Filings

$JNJ
Press Releases

$JNJ
Financials

$JNJ
Insider Trading

$JNJ
FDA approvals

$JNJ
Leadership Updates

$JNJ
Market Insights

$JNJ
Large Ownership Changes